Prognostic implication of outpatient loop diuretic dose intensification trajectories in patients with chronic heart failure

被引:0
作者
Koike, Toshiharu [1 ]
Suzuki, Atsushi [1 ]
Kikuchi, Noriko [1 ]
Yoshimura, Asami [1 ]
Haruki, Kaoru [1 ]
Yoshida, Ayano [1 ]
Sone, Maiko [1 ]
Nakazawa, Mayui [1 ]
Tsukamoto, Kei [1 ]
Imamura, Yasutaka [1 ]
Hattori, Hidetoshi [1 ]
Kogure, Tomohito [1 ]
Yamaguchi, Junichi [1 ]
Shiga, Tsuyoshi [1 ,2 ]
机构
[1] Tokyo Womens Med Univ, Dept Cardiol, 8-1 Kawada Cho,Shinjuku Ku, Tokyo 1628666, Japan
[2] Jikei Univ, Sch Med, Dept Clin Pharmacol & Therapeut, 3-25-8 Nishi Shinbashi,Minato ku, Tokyo 1058461, Japan
来源
IJC HEART & VASCULATURE | 2025年 / 57卷
关键词
Heart failure; Loop diuretics; Dose titration; Trajectory; Prognosis; MORTALITY; THERAPY; ASSOCIATION; OUTCOMES;
D O I
10.1016/j.ijcha.2025.101632
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The relationship between outpatient oral loop diuretic (OLD) dose intensification trajectories and the prognosis of patients with chronic heart failure (CHF) remains unclear. Methods: In 832 patients with CHF, OLD dose trajectories for 1 year were consecutively investigated. OLD dose intensification was defined as the first occurrence of OLD dose increase from the baseline within the first year. Patients were classified into three groups of OLD dose intensification trajectories: irreversible, reversible, and no intensification. Irreversible intensification was defined as an OLD dose intensification wherein the dose remained above the baseline during the first year of follow-up. Reversible intensification referred to an OLD dose intensification wherein the dose returned to or dropped below the baseline within the first year of follow-up. No intensification was defined as no OLD dose intensification throughout the first year of follow-up. The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular death (CVD), heart failure hospitalisation (HFH), a composite of CVD or HFH, and a composite of all-cause mortality or HFH after 1 year. Results: During the median follow-up (57 [range, 13-102] months), 146 patients died. Irreversible intensification was associated with higher risks of all outcomes than no intensification (e.g., all-cause mortality: hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.08-2.44; HFH: HR, 2.16; 95% CI, 1.65-2.98; CVD or HFH: HR, 2.17; 95% CI, 1.59-2.96). Conversely, reversible intensification had comparable prognoses for all outcomes to no intensification. Conclusion: OLD dose intensification trajectories could stratify the prognosis of CHF patients.
引用
收藏
页数:8
相关论文
共 31 条
[1]   Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization [J].
Abdel-Qadir, Husam M. ;
Tu, Jack V. ;
Yun, Lingsong ;
Austin, Peter C. ;
Newton, Gary E. ;
Lee, Douglas S. .
AMERICAN HEART JOURNAL, 2010, 160 (02) :264-U80
[2]   Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods [J].
Ahmed, Ali ;
Husain, Ahsan ;
Love, Thomas E. ;
Gambassi, Giovanni ;
Dell'Italia, Louis J. ;
Francis, Gary S. ;
Gheorghiade, Mihai ;
Allman, Richard M. ;
Meleth, Sreelatha ;
Bourge, Robert C. .
EUROPEAN HEART JOURNAL, 2006, 27 (12) :1431-1439
[3]   Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients [J].
Cautela, Jennifer ;
Tartiere, Jean-Michel ;
Cohen-Solal, Alain ;
Bellemain-Appaix, Anne ;
Theron, Alexis ;
Tibi, Thierry ;
Januzzi, James L., Jr. ;
Roubille, Francois ;
Girerd, Nicolas .
EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (08) :1357-1365
[4]   Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance [J].
Cohen-Solal, Alain ;
Jacobson, Arnold F. ;
Pina, Ileana L. .
ESC HEART FAILURE, 2017, 4 (04) :499-506
[5]   Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions - Part I: Loop Diuretics [J].
Cuthbert, Joseph James ;
Clark, Andrew L. .
CURRENT HEART FAILURE REPORTS, 2024, 21 (02) :101-114
[6]   Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction [J].
Damman, Kevin ;
Kjekshus, John ;
Wikstrand, John ;
Cleland, John G. F. ;
Komajda, Michel ;
Wedel, Hans ;
Waagstein, Finn ;
McMurray, John J. V. .
EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (03) :328-336
[7]   Influence of administration time and sex on natriuretic, diuretic, and kaliuretic effects of diuretics [J].
Dutta, Pritha ;
Sadria, Mehrshad ;
Layton, Anita T. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2023, 324 (03) :274-286
[8]   Relation of loop diuretic dose to mortality in advanced heart failure [J].
Eshaghian, Shervin ;
Horwich, Tamara B. ;
Fonarow, Gregg C. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12) :1759-1764
[9]   Diuretic Therapy for Patients With Heart Failure JACC State-of-the-Art Review [J].
Felker, G. Michael ;
Ellison, David H. ;
Mullens, Wilfried ;
Cox, Zachary L. ;
Testani, Jeffrey M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (10) :1178-1195
[10]   Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT [J].
Ferreira, Joao Pedro ;
Liu, Jiankang ;
Claggett, Brian L. ;
Vardeny, Orly ;
Pitt, Bertram ;
Pfeffer, Marc A. ;
Solomon, Scott D. ;
Zannad, Faiez .
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) :378-384